Back

The additional value of sacubitril/valsartan in fusion pacing CRT

19 May 2025 (12:25 - 13:34)
Organised by: Logo
Congress Presentation Part of: ePosters in chronic heart failure - treatment (2) Cardiac Resynchronisation Therapy (CRT) HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Andreea Faur

Victor Babes University of Medicine and Pharmacy, Timisoara (Romania)

6 More presentations in this session

Presentation thumbnail
Impact of optimized medical therapy on ICD shocks and survival in heart failure patients
Doctor P. Bernardes (Setubal, PT)
Abstract Slides Video
Presentation thumbnail
Evaluating superresponse in CRT: a clinical edge or just a remodeling effect?
Doctor S. Andraz (Faro, PT)
Abstract Slides Video
Presentation thumbnail
Alert rate characteristics of a dynamic multiparameter heart failure risk score in a real-world cohort: results from the TriageHF Post Approval Study
Doctor C. Love (Baltimore, US)
Abstract Slides Video
Presentation thumbnail
home-based digital cardiac rehabilitation following step down from the acute heart failure virtual ward
Doctor R. Sankaranarayanan (Liverpool, GB)
Abstract Slides Video
Presentation thumbnail
Incidence of ventricular arrhythmias in ICD patients after improvement of left ventricular ejection fraction: a longitudinal study
Doctor J. Quintal (Setubal, PT)
Abstract Slides Video

Access the full session

Session thumbnail
ePosters in chronic heart failure - treatment (2)

The Event

Event poster

Heart Failure 2025

19 May 2025 12:25 CET
You may be interested in
thumbnail
Congress Presentation
Effect of sacubitril/valsartan and SGLT2 inhibitors on echocardiographic response and clinical outcomes after cardiac resynchronization therapy: insights from a real-world cohort
thumbnail
Congress Presentation
The positive effect of sacubitril/valsartan therapy on QRS width and QTC interval on electrocardiogram in heart failure patients with reduced ejection fraction
thumbnail
Congress Presentation
Cardiac resynchronization therapy, remodeling and outcome in patients with amyloid transthyretin cardiomyopathy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources